Wall Street brokerages expect that Miragen Therapeutics Inc (NASDAQ:MGEN) will report earnings per share of ($0.35) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Miragen Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.32). Miragen Therapeutics posted earnings per share of ($0.18) in the same quarter last year, which suggests a negative year over year growth rate of 94.4%. The firm is scheduled to report its next quarterly earnings report on Wednesday, May 8th.
According to Zacks, analysts expect that Miragen Therapeutics will report full year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.54) to ($0.93). For the next year, analysts expect that the business will report earnings of ($1.41) per share, with EPS estimates ranging from ($1.83) to ($0.77). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Miragen Therapeutics.
Miragen Therapeutics (NASDAQ:MGEN) last posted its quarterly earnings results on Wednesday, March 13th. The medical research company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.02). Miragen Therapeutics had a negative net margin of 389.97% and a negative return on equity of 51.82%. The firm had revenue of $0.48 million for the quarter, compared to analysts’ expectations of $1.54 million.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research cut shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, January 15th. ValuEngine cut shares of Miragen Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, April 1st. B. Riley assumed coverage on shares of Miragen Therapeutics in a report on Monday, December 31st. They set a “buy” rating and a $18.50 price target on the stock. Robert W. Baird assumed coverage on shares of Miragen Therapeutics in a report on Friday, January 4th. They set an “outperform” rating on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $24.00 price target (up previously from $22.00) on shares of Miragen Therapeutics in a report on Monday, March 18th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $16.19.
A number of hedge funds have recently modified their holdings of MGEN. Bank of America Corp DE boosted its holdings in Miragen Therapeutics by 35.9% in the fourth quarter. Bank of America Corp DE now owns 33,116 shares of the medical research company’s stock worth $100,000 after purchasing an additional 8,756 shares during the last quarter. Rhumbline Advisers boosted its holdings in Miragen Therapeutics by 51.4% in the fourth quarter. Rhumbline Advisers now owns 33,350 shares of the medical research company’s stock worth $101,000 after purchasing an additional 11,321 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Miragen Therapeutics in the fourth quarter worth approximately $179,000. SG Americas Securities LLC boosted its holdings in Miragen Therapeutics by 7.2% in the fourth quarter. SG Americas Securities LLC now owns 99,324 shares of the medical research company’s stock worth $301,000 after purchasing an additional 6,662 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Miragen Therapeutics by 59.1% in the fourth quarter. Bank of New York Mellon Corp now owns 99,844 shares of the medical research company’s stock worth $302,000 after purchasing an additional 37,101 shares during the last quarter. Institutional investors own 47.45% of the company’s stock.
Shares of NASDAQ:MGEN traded down $0.10 during trading on Friday, reaching $2.73. 170,948 shares of the stock traded hands, compared to its average volume of 194,995. Miragen Therapeutics has a 52-week low of $2.20 and a 52-week high of $7.94. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.16. The stock has a market cap of $84.41 million, a price-to-earnings ratio of -2.48 and a beta of 1.21.
Miragen Therapeutics Company Profile
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Read More: What is the strike price in options trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.